Inventiva (IVA) Granted FDA's Fast Track Designation of lanifibranorin NASH Encompasses the Treatment of NASH with Compensated Cirrhosis

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/13/2026

1. ADBE
2. SPCX
3. USO
4. SPY
5. RH
6. NVDA
7. RKLB
8. CRM
9. MSFT
10. DOL:CN

Go back to Inventiva (IVA) Granted FDA's Fast Track Designation of lanifibranorin NASH Encompasses the Treatment of NASH with Compensated Cirrhosis

Inventiva announces FDA decision that Fast Track designation granted to lanifibranor in NASH encompasses the treatment of NASH with compensated cirrhosis

September 21, 2021 4:00 PM EDT

The FDA decision follows the Companys Fast Track designation request for lanifibranor in NASH with compensated cirrhosis filed in August 2021

Daix (France), Long Island City (New York, United States), September 21, 2021 Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS) and other diseases with significant unmet medical need, today announced that the U.S. Food and Drug Administration (FDA) has decided that the Fast Track designation previously granted... More